These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 6073947)
61. Clinical protocol of human gene transfer for hemophilia B. Hsueh JL Hum Gene Ther; 1992 Oct; 3(5):543-52. PubMed ID: 1420453 [No Abstract] [Full Text] [Related]
62. [Effect of preparation PPSB on coagulation and hemostasis in hemophilia B patients]. Tarasova LN; Sadkov SA; Porokhnenko SG Gematol Transfuziol; 1984 Aug; 29(8):22-4. PubMed ID: 6479558 [No Abstract] [Full Text] [Related]
63. Treatment of hemophilia B: serendipitous use of continuous infusion coagulation factor IX. Goldsmith JC; Gordon EM Thromb Res; 1993 May; 70(3):265-7. PubMed ID: 8327991 [No Abstract] [Full Text] [Related]
64. Insight into health-related quality of life of young children with haemophilia B treated with long-acting nonacog beta pegol recombinant factor IX. Carcao M; Kearney S; Santagostino E; Oyesiku JOO; Young NL; Meunier J; Hoxer CS; Zhang C; Blanchette VS Haemophilia; 2017 May; 23(3):e222-e224. PubMed ID: 28371032 [No Abstract] [Full Text] [Related]
65. The international factor IX treatment network survey. Berntorp E; Shapiro AD; Waters J; Astermark J; Haemophilia; 2012 May; 18(3):e60-2. PubMed ID: 22404549 [No Abstract] [Full Text] [Related]
66. A safe approach to treatment of factor IX-deficient patients. Introduction and overview of treatment. Aledort LM Semin Hematol; 1991 Jul; 28(3 Suppl 6):1-2. PubMed ID: 1780765 [No Abstract] [Full Text] [Related]
67. Factor IX Padua for haemophilia B gene addition: universal adaptation and repeated success. George LA Lancet Haematol; 2022 Jul; 9(7):e465-e466. PubMed ID: 35772422 [No Abstract] [Full Text] [Related]
68. Recombinant versus plasma-derived factor IX in the treatment of hemophilia B: proceedings of a meeting held in June 2003. Mathew P; Altisent C Blood Coagul Fibrinolysis; 2004 Jun; 15 Suppl 2():S1-3. PubMed ID: 15322449 [No Abstract] [Full Text] [Related]
69. Editorial: Clinical concentrates of clotting-factor IX. Lancet; 1975 Nov; 2(7940):855-6. PubMed ID: 53334 [No Abstract] [Full Text] [Related]
70. Preparation and properties of a therapeutic factor IX concentrate. Suomela H; Myllylä G; Raaska E Vox Sang; 1977 Jul; 33(1):37-50. PubMed ID: 883244 [TBL] [Abstract][Full Text] [Related]
72. Delayed seroconversion to HIV in a hemophiliac. von Hintzenstern J; Jahn G; Mang K; Harms D; Fleckenstein B Klin Wochenschr; 1988 May; 66(9):410-1. PubMed ID: 3164792 [TBL] [Abstract][Full Text] [Related]
73. Hemophilia B diagnosed by hematoma at the columella base. Kuwahara M; Yurugi S; Takeda M; Fukuda K; Yoshioka A Plast Reconstr Surg; 2006 Apr; 117(5):1647-8. PubMed ID: 16641746 [No Abstract] [Full Text] [Related]
74. Coronary artery bypass surgery, angioplasty and long term anti-platelet treatment in a type B hemophilia patient. Pesaro AE; Gaz MV; Karbstein R; Perin M; Serrano CV; Damico E Clinics (Sao Paulo); 2009; 64(8):822-3. PubMed ID: 19690670 [No Abstract] [Full Text] [Related]
75. Factor IX deficiency and anaphylaxis. Stones DK; McGill N S Afr Med J; 2000 Jan; 90(1):50. PubMed ID: 10721392 [No Abstract] [Full Text] [Related]
76. [Treatment of hemophilia B with PPSB]. Loeliger EA; Mattern MJ; Hensen A; Hemker HC Blut; 1968 Feb; 16(5):289-97. PubMed ID: 5647965 [No Abstract] [Full Text] [Related]